
    
      Transplantation of related or unrelated allogeneic peripheral blood stem cells (PBSCs) after
      administration of a reduced-intensity regimen of busulfan, melphalan and alemtuzumab will be
      associated with satisfactory engraftment and acceptable post-transplant non-relapse
      mortality.
    
  